## Gene Summary
DDX58, also known as RIG-I, stands for DEAD (Asp-Glu-Ala-Asp) box polypeptide 58. It is a member of the DExD/H box RNA helicases, which are typically involved in various aspects of RNA processing. DDX58 is critically important in innate immunity as it detects viral RNA in the cytoplasm, leading to the production of interferons and other cytokines essential for the defense against viruses. It recognizes RNA with 5'-triphosphates, distinguishing viral RNA from self-RNA. DDX58 is widely expressed across various tissues but is predominantly noted in immune cells.

## Gene Drugs, Diseases, Phenotypes, and Pathways
DDX58 plays a significant role in numerous immune response pathways, particularly those relating to antiviral defense mechanisms. The activation of DDX58 due to viral RNA detection leads to engagement with proteins like MAVS, which in turn activates NF-κB and IRF3, pivotal transcription factors for cytokine production. This pathway underscores its essential function during viral infections such as influenza and other RNA viruses. Dysfunction or aberrant expression of DDX58 is implicated in autoimmune diseases and may influence susceptibility to viral infections. DDX58’s involvement in these pathways makes it a potential therapeutic target for modulating immune responses and viral infection treatments.

## Pharmacogenetics
The pharmacogenetics of DDX58 is particularly relevant when considering its role in viral infections and influence on immune responses. Although specific drug-gene interactions at the clinical pharmacogenetics level are not extensively documented for DDX58, its modulation is considered in therapies aimed at enhancing antiviral defense or damping hyperactive immune responses in conditions like autoimmune disorders. DDX58’s mechanism suggests that agents which can modulate its RNA sensing or signaling activity could be crucial in developing treatments against RNA viruses, possibly affecting the efficacy and response rates to these antiviral therapies. Optimizing and personalizing treatments based on DDX58 activity can potentially improve outcomes in viral and inflammatory diseases.